Preclinical toxicologic evaluation of 2,5-piperazinedione, 3,6-bis(5-chloro-2-piperidyl),-dihydrochloride (NSC-135758) in dogs and monkeys.
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000633:toxicity*; D001219:Aspartate Aminotransferases / Q000097:blood; D001806:Blood Urea Nitrogen; D001853:Bone Marrow / Q000187:drug effects; D001854:Bone Marrow Cells; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D005260:Female; D000882:Haplorhini; D007275:Injections, Intravenous; D007413:Intestinal Mucosa / Q000187:drug effects; D007928:Lethal Dose 50; D007970:Leukopenia / Q000139:chemically induced; D008206:Lymphatic Diseases / Q000139:chemically induced; D008221:Lymphoid Tissue / Q000187:drug effects; D008251:Macaca; D008297:Male; D010879:Piperazines / Q000008:administration & dosage / Q000633:toxicity*; D010880:Piperidines / Q000008:administration & dosage / Q000633:toxicity*; D013997:Time Factors
D000903:Antibiotics, Antineoplastic; D010879:Piperazines; D010880:Piperidines; D001219:Aspartate Aminotransferases